BeyondSpring Stock Is Up More than 300%: What You Need To Know?

BeyondSpring Inc BYSI is trading over 300% up during premarket in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in combination with docetaxel.
The trial includes patients 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type.
The data showed that compared to docetaxel alone, the combination increased the overall survival (primary endpoint) and met key secondary endpoints, including significantly improving ORR, PFS, and 24- and 36-month OS rates.
Results also demonstrated a reduction in severe/life-threatening neutropenia events (5.3% combo therapy vs. 27.8% docetaxel alone).
24 Month overall survival (OS) rate (22.1% vs. 12.5%). 36 Month OS rate (11.7% vs. 5.3%), and 48 Month OS rate (10.6% vs. 0%).
BeyondSpring’s management will host a conference call and webcast today at 8:30 a.m. Eastern Time.
Price Action: BYSI shares are up 303.4% at $38.85 during the premarket session on the last check Wednesday.